Transforming growth factor-β and connective tissue growth factor: Key cytokines in scleroderma pathogenesis

Current Opinion in Rheumatology

Volumn 13, Issue 6, 2001, Pages 505-511

  Denton, Christopher P ^a   Abraham, David J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

CELL MIGRATION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SYSTEMIC SCLEROSIS;

DNA-BINDING PROTEINS; GROWTH SUBSTANCES; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MULTIGENE FAMILY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SMAD3 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035161153     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200111000-00010     Document Type: Review

References (52)

1. Divergence and convergence of TGF-beta/BMP signaling
2. Growth factors from murine sarcoma-transformed cells
3. Specificity, diversity, and regulation in TGF-beta superfamily signaling
4. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring
5. The role of cytokines in the pathogenesis of rheumatoid arthritis
6. Mads and Smads in TGF beta signaling
7. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor
8. Controlling TGF-beta signaling
9. A strategy for determining the pathogenesis of systemic sclerosis: Is transforming growth factor beta the answer?
10. Plasma TGF beta in systemic sclerosis: A cross-sectional study
11. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: A mediator of fibrosis?
12. Co-localization of transforming growth factor beta 2 with alpha 1 (I) procollagen mRNA in tissue sections of patients with systemic sclerosis
13. Immunocytochemical localization and serologic detection of transforming growth factor beta 1: Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon
14. Evaluation of transforming growth factor beta and type I procellagen gene expression in fibrotic skin diseases by in situ hybridization
15. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma
16. Collagen type I is not under autocrine control by transforming growth factor-beta 1 in normal and scleroderma fibroblasts
17. Spontaneous increase in TGF-β production by bronchoalveolar mononuclear cells of patients with systemic autoimmune diseases affecting the lung
18. Transforming growth factor beta within fibrotic scleroderma lungs
19. Localisation of transforming growth factor beta(1) and beta(3) mRNA transcripts in normal and fibrotic human lung
20. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders
21. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis
22. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: Association with an Amerindian HLA haplotype
23. Microsatellites and intragenic polymorphisms of transforming growth factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (sclerederma): A preliminary analysis showing no genetic association
24. Analysis of TGFβ1 gene polymorphisms in patients with limited and diffuse scleroderma
25. Increased expression of TGF-beta receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype
26. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor beta receptors
27. Interaction of smad3 with a proximal smadbinding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta
28. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis
29. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma
30. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters
31. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis
32. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin
33. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes
34. New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse
35. The cutaneous microfibrillar apparatus contains latent transforming growth factor-beta binding protein-1 (LTBP-1) and is a repository for latent TGF-beta1
36. Characterization of mutated protein encoded by partially duplicated fibrillin-1 gene in tight skin (TSK) mice
37. Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse
38. Activation of a fibroblast-specific enhancer of the proα2(I)collagen gene in tight-skin mice
39. Connective tissue growth factor: A cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10
40. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts
41. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor
42. The CON family of genes: A brief history
43. Connective tissue growth factor gene expression in tissue sections from localised scleroderma, keloid, and other fibrotic diseases
44. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis
45. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis
46. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis
47. Iloprost suppresses CTGF production in fibroblasts and in the skin of scleroderma patients
48. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene
49. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling
50. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis
51. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
52. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts